


BROOKS LABORATORIES LIMITED

Regd office: G 101, Ivory Tower, Sector 70, Mohali, Punjab

Statement of Audited Financial Results for the Year Ended 31st March, 2012

		(₹ in Lacs)			
	Particulars	Quarter Ended		Accounting Year Ended	
		Unaudited		Audited	
		31/03/2012	31/12/2011	31/03/2012	31/03/2011
1	Income from operations				
	(a) Net sales/income from operations (Net of excise duty)	1,448	1,554	5,608	5,254
	(b) Other operating income	-	-	-	-
	Total income from operations (net)	1,448	1,554	5,608	5,254
2	Expenses				
	(a) Cost of materials consumed	956	960	3,603	3,746
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress	- 111	58	28	- 42
	(d) Employee benefits expense	95	69	273	239
	(e) Depreciation and amortisation expense	17	16	66	61
	(f) other Administrative Expenses	208	196	641	383
	Total expenses	1,165	1,300	4,611	4,388
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	283	254	997	866
4	Other income	22	53	92	13
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	305	308	1,089	879
6	Finance costs	42	- 5	172	149
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	263	303	917	730
8	Exceptional items	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7-8)	263	303	917	730
10	Tax expense				
	-Current Tax	52	61	183	145
	-MAT Credit Unutilized	49	56	170	131
11	-Deferred Tax	10	3	20	16
12	Extraordinary items	-	-	-	11
13	Net Profit / (Loss) for the period (11 + 12)	250	295	884	689
14	Share of profit / (loss) of associates*	-	-	-	-
15	Minority interest *	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	250	295	884	689

[Handwritten Signature]
1/05/12



17	Paid-up equity share capital (Face Value Rs.10/- per share)	1,619	1,619	1,619	989
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	7,508	954
19.i	Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):				
	(a) Basic -in Rs.	2.62	3.12	6.55	7.08
	(b) Diluted- in Rs.	2.62	3.12	6.55	7.12
19.ii	Earnings per share (after extraordinary items) (of Rs.10/- each) (not annualised):				
	(a) Basic -in Rs.	2.62	3.12	6.55	6.97
	(b) Diluted- in Rs.	2.62	3.12	6.55	7.00
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	-Number of shares	6350000	6350000	6350000	50000
	-Percentage of shareholding	39.23	39.23	39.23	0.51
2	Promoters and Promoter Group Shareholding				
	a) Pledged / Encumbered				
	-Number of shares	0	0	0	0
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0	0	0	0
	-Percentage of shares (as a % of the total share capital of the company)	0	0	0	0
	b) Non - encumbered				
	-Number of shares	9836422	9836422	9836422	9836422
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100
	-Percentage of shares (as a % of the total share capital of the company)	60.77	60.77	60.77	99.49
B	INVESTOR COMPLAINTS				
		Quarter ended 31/03/2012			
	Pending at the beginning of the quarter	Nil			
	Received during the quarter	Nil			
	Disposed of during the quarter	Nil			
	Remaining unresolved at the end of the quarter	Nil			

Handwritten signature



(₹In Lacs)

Audited Statement of Assets and Liabilities		As at (31/03/2012)	As at (31/03/2011)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	1,619	989
	(b) Reserves and surplus	7,508	954
	(c) Money received against share warrants	-	-
	Sub-total - Shareholders' funds	9,126	1,943
2	Share application money pending allotment	-	-
3	Minority interest *	NA	NA
4	Non-current liabilities		
	(a) Long-term borrowings	-	90
	(b) Deferred tax liabilities (net)	121	102
	(c) Other long-term liabilities	-	-
	(d) Long-term provisions	-	-
	Sub-total - Non-current liabilities	121	192
5	Current liabilities		
	(a) Short-term borrowings	-	776
	(b) Trade payables	724	703
	(c) Other current liabilities	116	187
	(d) Short-term provisions	493	286
	Sub-total - Current liabilities	1,333	1,952
	TOTAL - EQUITY AND LIABILITIES	10,580	4,087
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	5,601	1,972
	(b) Goodwill on consolidation *	NA	NA
	(c) Non-current investments	2	2
	(d) Deferred tax assets (net)	-	-
	(e) Long-term loans and advances	593	379
	(f) Other non-current assets	327	43
	Sub-total - Non-current assets	6,522	2,396
2	Current assets		
	(a) Current investments	-	-
	(b) Inventories	516	550
	(c) Trade receivables	1,076	696
	(d) Cash and cash equivalents	1,868	87
	(e) Short-term loans and advances	598	357
	(f) Other current assets	-	-
	Sub-total - Current assets	4,058	1,691
	TOTAL - ASSETS	10,580	4,087

[Handwritten Signature]



Detail of cost of Project status as on 31th March 2012.

(₹In lacs)

Sr.No.	Object	Total Estimated Cost	Actual Utilizations
1	Land	635	398
2	Building Construction	1,220	1,200
3	Plant & Machinery	1,994	547
4	Utilities	1,100	850
5	Misc. Fixed Assets	230	200
6	Long term working capital	500	NIL
7	General corporate purposes	328	34
8	Listing Fees to Stock Exchanges	1	1
9	Issue Expenses	292	292
	Total Cost of the Project	6,300	3,522

1/3/12
1/3/12



Notes:

- 1) The above result for the period ended 31st March 2012, as reviewed by the Audit Committee, and were considered and approved by the Board of Directors at its meeting held on 29th May 2012.
- 2) As the company's business activity falls within a single primary business segment "Pharmaceutical Formulations" the Disclosure Requirement of Accounting Standard (AS-17) "Segment Reporting" is not applicable.
- 3) The figures pertaining to the quarter ended 31.03.2012 are the balancing figures between the audited Figures in respect of the financial year ended 31.03.2012 and published year to date figures upto the end of third quarter ended 31.12.2011 of the financial year.
- 4) Figures for the previous year/period have been regrouped, wherever necessary.
- 5) The company did not have any investor complaints pending as on 31st March 2012, there were no investor's complaints received during the quarter ended 31st March 2012.
- 6) The Equity Shares of the company got listed on BSE and NSE as on 5th September 2011 hence figure for the corresponding quarter ended 31st March 2011 are not given.

Place: MUMBAI

Date: 29th MAY 2012

FOR BROOKS LABORATORIES LIMITED



A handwritten signature in black ink, appearing to read "Rajesh Mahajan".

MANAGING DIRECTOR

MR. RAJESH MAHAJAN